| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, Regenerative Med. | EVP, Research and Development | Director +1 more
3 companies
Robert Benjamin Stein is President, Regenerative Med. at MDXG, with reported holdings spanning 3 companies. Robert Benjamin Stein's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.3M at current prices.
Our model assigns Robert Benjamin Stein a below-average insider score of 43/100, based on 14 past trades. Over a 12-month horizon, 14.3% of those trades were profitable, with an average 12-month return of -55.0%.
Robert Benjamin Stein's largest disclosed position is in MDXG as President, Regenerative Med., worth about $1.0M. The MDXG filings lean toward selling, a net 186,901 shares.
Robert Benjamin Stein has 26 Form 4 filings on record from February 2015 to July 2026, across 4 companies: Director at PolyPid (PYPD), 2026; Director at Protagenic Therapeutics, Inc.\new (PTIX), 2016–2024; President, Regenerative Med. at Mimedx Group (MDXG), 2020–2023, and 1 more.
The 30 reported transactions were 14 open-market sales, 9 option or other derivative awards, 6 stock awards and 1 disposition back to the company.
Counted by filing, the open-market trades come to no purchases and 12 sales worth about $907K.
The largest open-market sale was 51,756 shares of MDXG at an average $5.34 on May 4, 2023, about $276K. Twelve months later MDXG was up 33%.
None of the 5 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 16, 2023 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 13,972 | $6.00 | $83,797.61 | -4.2% | +24.7% | +34.9% | |
| May 10, 2023 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 5,869 | $5.93 | $34,780.28 | -1.7% | +21.0% | +19.5% | |
| May 4, 2023 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 51,756 | $5.34 | $276,470.20 | -13.3% | +39.2% | +33.3% | |
| Apr 25, 2023 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 5,987 | $3.74 | $22,415.33 | -1.5% | +103.8% | +75.7% | |
| Apr 11, 2023 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 5,996 | $3.31 | $19,846.76 | -1.5% | +100.3% | +98.5% | |
| Mar 7, 2023 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 12,355 | $4.24 | $52,442.03 | -4.4% | +38.6% | +92.1% | |
| Sep 13, 2022 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 27,329 | $3.44 | $94,069.02 | -8.9% | -8.7% | +119.9% | |
| Aug 12, 2022 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 8,503 | $4.04 | $34,343.62 | -2.7% | -22.5% | +82.4% | |
| Aug 4, 2022 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 19,500 | $3.62 | $70,590.00 | -5.8% | -27.2% | +104.0% | |
| Jun 28, 2022 | MDXG Mimedx Group, Inc. | President, Regenerative Med. | Sell | 14,600 | $3.47 | $50,662.00 | -4.2% | -22.1% | +84.5% |